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Clinical Trial: VADS from pg. 2

Clinical trial: Team investigates
stroke risk in heart failure patients with VADs
The work is being conducted through
Aurora St. Luke’s Mechanical Circulatory
Support Program.
“Since 1986, when the hospital’s program
started, Aurora St. Luke’s has been
involved in every major mechanical
circulatory support trial conducted in
the United States. That record continues
today. It speaks to the administrative
commitment and quality of the many
caregivers involved in the program here at
Aurora St. Luke’s,” Dr. Downey said.
The goal of this prospective, randomized,
controlled, unblinded, multicenter trial is
to enroll about 465 subjects who have
advanced heart failure and controlled
blood pressure. Of these, a portion will be
randomized to receive an FDA-approved
LVAD and the remainder will receive
the HeartWare VAD, an implantable
centrifugal pump that was designed to
provide flows up to 10 L/min in a small,
lightweight device.

Frank Downey, MD
Surgical Director of
Cardiac Transplantation
and Mechanical
Circulatory Support

Cheryl Zywicki,
RN, CCRC
Certified Clinical
Research Coordinator

In the U.S., the HeartWare VAD System is
an investigational device limited by federal
law to investigational use. HeartWare has
indicated that it intends to incorporate
data from the supplemental trial into a
pre-market approval application seeking
approval for the HeartWare VAD System
for the destination therapy indication.
Patients will be followed for 12 months
after implantation.
Investigators will track the number of strokes
experienced by subjects in the 12 months
following the implantation of a VAD.
Clinicians treating subjects with
advanced heart failure with optimally
controlled blood pressure can obtain
more information about this study by
contacting Certified Clinical Research
Coordinator Cheryl A. Zywicki, RN,
CCRC, at 414-385-2474 or
cheryl.zywicki@aurora.org. ■

As part of an international clinical
trial, researchers at Aurora St. Luke’s
Medical Center are studying whether a
regenerative medicine therapy using
stem cells is effective in treating chronic
heart failure.
Principal investigators Nasir Z.
Sulemanjee, MD, and Suhail Q. Allaqaband,
MD, and their team are participating in an
interventional trial to establish the efficacy
and long-term safety of trans-endocardial
delivery of allogeneic human bone
marrow-derived mesenchymal precursor
cells (MPCs) in subjects with chronic
heart failure due to left ventricular systolic
dysfunction (clinicaltrials.gov
identifier: NCT02032004).
The goal of this randomized, double-blind
clinical trial is to enroll 1,730 subjects with
chronic heart failure throughout
24 countries.
Subjects will be randomly assigned
to undergo a cardiac catheterization
involving delivery of these specialized
stem cells (CEP-41750) directly into
the heart muscle using a sophisticated
mapping and injection procedure, or to a
sham arm.

HeartWare Ventricular Assist Device System
(HeartWare, Framingham, Massachusetts)
Caution: The HeartWare VAD System is an
investigational device limited by federal law to
investigational use.
Image courtesy of HeartWare.

Aurora Cardiovascular Services Heart Failure Procedures
Bridge-to-Transplant and
Destination Therapy Ventricular Assist
Devices (VADs)
2014

Clinical trial:
Researchers study
new use of stem cells
in heart failure patients
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Dr. Sulemanjee affirmed that “through
numerous clinical and preclinical studies,
we have come to realize the potential of
stem cells to help patients suffering from
cardiovascular disease, especially in the
treatment of heart failure. This research
study will help us to further investigate
this technology and therapy.”

“Through numerous clinical and
preclinical studies, we have come
to realize the potential of stem
cells to help patients suffering
from cardiovascular disease,
especially in the treatment of
heart failure.”
Nasir Z. Sulemanjee, MD
continued on pg. 5
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Student researchers get intensive lesson in
laboratory procedures, processes

Arshad Jahangir, MD
Vinay Thohan, MD
Director of the Sheikh
Director of Advance
Khalifa bin Hamad
Heart Failure Therapies
Al Thani Center for
Integrative Research on
Cardiovascular Aging

Alessandra DeFranco
Student Researcher

Kingshuk Mazumdar
Student Researcher

Tess Battiola of the University of Wisconsin-Madison gains research experience at Aurora’s Sheikh
Khalifa bin Hamad Al Thani Center for Integrative Research on Cardiovascular Aging.

As Arshad Jahangir, MD, and his staff
of researchers continued to explore the
mechanisms of aging-related cardiac
dysfunction and reparative processes
in 2014, they were joined by a group of
enthusiastic students from across
the nation.
The students, from the undergraduate
to post-graduate level, participated for
10 weeks in ongoing projects and were
mentored by the scientists and physicians
at the Sheikh Khalifa bin Hamad Al
Thani Center for Integrative Research on
Cardiovascular Aging.
The 13 students, from institutions including
the University of Wisconsin-Madison,
Northwestern University, Johns Hopkins
University, University of Minnesota,
Marquette University and Mount
Holyoke College, worked with Aurora
Cardiovascular Services scientists as part
of Aurora Research Institute’s mission to
advance scientific knowledge. In addition,
a science teacher from Marquette
University High School in Milwaukee
worked along with the students.

“It is always exciting to work with young
minds who are inquisitive and eager
to learn,” said Dr. Jahangir, the center’s
director. “They not only learned the
basic biology of cardiovascular aging
and technical skills such as confocal
microscopy, Western blot, PCR, patchclamp electrophysiology, and cell and
mitochondrial isolation from heart tissue, but
also how to use scientific methodology
to ask and answer a question and present
their results to their colleagues.”
Each Friday, the student researchers met
with faculty to review their work thus far.
“I think the Friday meetings were a great
way to learn about the need to defend
one’s work and be confident in their data,
but also to be open and willing to hear
suggestions from others,” said student
researcher Tess Battiola of the University
of Wisconsin-Madison.
The students assisted with research
projects that examined the role of
mitochondria in cardiac dysfunction, ion
channel dysfunction and cardiac fibrosis
and helped develop a model of alcoholic
cardiomyopathy.
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“This experience allowed me to become
much more involved in laboratory
protocols than I imagined I could at this
age,” said Kingshuk Mazumdar, a student
researcher from Union College.
In addition to the summer fellowship
program, Aurora Cardiovascular
Services with Aurora Research Institute
also offered a summer student intern
program through which UW-Madison
statistics major Lydia Garlie worked with
Vinay Thohan, MD, and Scarlet Shi, PhD.
Garlie reviewed records for appropriate
shocks in patients who received an
implantable cardioverter-defibrillator and
determined the possible association of
echocardiographic measures of cardiac
function to ICD shock.
“One in seven patients with a defibrillator
will receive a life-saving shock for
arrhythmia,” Dr. Thohan said.
“This research allows us to better
understand who those people are with
currently available technologies. In the
future, we may be able to target this
high-risk population for therapies to
prevent dangerous arrhythmias.” ■

Hybrid aortic work continues at Aurora St. Luke’s
Patient, 49, doing well after arch replacement
The term hybrid refers to combining
traditional open surgery with
percutaneous technologies to treat a
patient’s condition in a novel and often
less invasive way.

aneurysm of her aortic arch (Figure 1). The
location of her aneurysm made traditional
open surgical approaches extremely high
risk; consequently, she had been denied
care by several other centers.

There is perhaps no better application for
hybrid procedures than in the treatment
of complex aortic arch aneurysms. Eric
Weiss, MD, a new cardiac surgeon with
Aurora Cardiovascular Services who
specializes in surgery of the thoracic
aorta, recently applied this technique
in aortic surgery at Aurora St. Luke’s
Medical Center.

“She was young and otherwise healthy,
and we had to get creative to identify a
solution to this problem,” Dr. Weiss said.
“A hybrid arch replacement was the best
strategy for her long-term health.”

The use of hybrid technologies represents
a substantial advance in the treatment of
aortic disease. With the recent opening of
two state-of-the-art hybrid suites and the
heart team’s focus on minimally invasive
approaches, Aurora St. Luke’s Medical
Center is poised to be a leader in aortic
surgery for years to come.

Dr. Weiss employed this strategy for a
49-year-old woman with a large dissecting

Dr. Weiss and his team replaced the
first part of the aortic arch and deployed
a thoracic endovascular stent directly into
the aorta to seal the aneurysm (Figure
2). Her recovery was excellent, and she
was discharged from the hospital free

The addition of Dr. Weiss to the St.
Luke’s team continues the medical
center’s tradition of providing the latest
techniques to treat aortic aneurysms and
novel approaches for patients deemed
previously inoperable. ■

Figure 1

Figure 2

from long-term sequelae relating to her
aneurysm, Weiss said

Eric Weiss, MD
Cardiothoracic Surgeon

Aneurysm and dissection of
distal aortic arch.

Thoracic stent deployed in hybrid
fashion to treat the aneurysm.
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Clinical trial: Researchers study new use of stem cells in heart failure patients
The clinical trial is sponsored
by Teva Pharmaceutical
Industries (Petah Tikva, Israel).
In the U.S., MPC treatment is an
investigational therapy limited by
federal law to investigational use.
Over a five-year period, Drs.
Sulemanjee and Allaqaband and
their team will carefully monitor all
enrolled patients for benefit and
improvement in their heart failure,
as well as learn of any major
adverse cardiac events in study
subjects. Some of the parameters
to be serially monitored

include two-dimensional
echocardiography and exercise
capacity with a 6-minute walk test.
Clinicians seeking information
about alternative options for
their patients diagnosed with
chronic heart failure, who they
feel may be interested or wanting
to participate in this research
study, should contact Certified
Clinical Research Coordinator
Don Lobacz, RN, CCRC,
at 414-649-3438 or
donald.lobacz@aurora.org. ■
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Suhail Allaqaband, MD
Program Director,
Cardiology Fellowship
Program

Nasir Z. Sulemanjee, MD
Advanced Heart
Failure and Transplant
Cardiologist, Director
of the Advanced Heart
Failure Fellowship
Program

Don Lobacz, RN, CCRC
Certified Clinical
Research
Coordinator
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Aurora Research Institute gives
start-up boosts for cardiovascular studies
Aurora Research Institute recently
awarded more than $200,000 to Aurora
Health Care investigators for new
cardiovascular-related research studies.
Awards were allocated in three categories.
The Cardiovascular Surgery Research
Award provides up to $50,000 per award
for patient-centered cardiovascular
surgery research. Recipients and the work
being funded:
• Ulugbek Negmadjanov, MD; examining
how disease causes heart repair cells
to produce excessive scar tissue,
which leads to complications after
heart surgery.
• Vinay Thohan, MD; identifying clinical
factors that may predict the development
of gastrointestinal bleeding in patients
with left ventricular assist devices
(LVADs).
• Nasir Z. Sulemanjee, MD;
studying clinical outcomes in patients
with an LVAD and kidney disease.

The Sullivan Cardiac Research Award
for Residents and Fellows provides
up to $30,000 per award to residents
and fellows under mentorship guidance
for patient-centered research of
cardiovascular diseases. The recipient is:

• Steven Port, MD, and Lily Honoris, MD;
determining whether computed
tomography angiography can
visualize and provide details about
plaque in the coronary arteries in
patients with end-stage kidney disease.

• Daniel Ortiz, MD; His project focuses
on implementing a new tool that
would assess the possibility for bleeding
in patients who undergo treatment for
blockages in leg arteries.

A scientific review committee comprising
researchers and clinicians evaluates
proposals based on overall impact of
the proposed study; its significance,
innovation and approach; and the
investigators involved in the research.

The Cardiac Research Award provides
up to $40,000 per award to basic and
clinical investigators and fellows under
mentorship guidance for patient-centered
research of cardiovascular diseases.
Recipients and their work:
• Vinay Thohan, MD; studying whether
Doppler imaging of heart function
can predict outcomes in patients
with heart failure who will undergo
noncardiovascular surgeries.

To learn more about
Aurora Research Institute’s intramural
cardiology awards, contact Vani Nilakantan,
PhD, at 414-219-7846 or
vani.nilakantan@aurora.org. ■
Vani Nilakantan, PhD
Director of InvestigatorInitiated Research/
Sponsored
Programs Office,
Aurora Research
Institute

JPCRR Call for Papers
Journal of Patient-Centered Research
and Reviews (JPCRR) is currently seeking
manuscript submissions from all fields of
medicine, including cardiology.
In addition to this general call for papers,
an upcoming theme issue of JPCRR
will focus on the specialty of Vascular
Medicine. Submissions on this topic are
strongly encouraged at this time. The
deadline for papers to be considered for
this theme issue is April 15, 2015.
A rigorously peer-reviewed quarterly
journal founded by Aurora Health Care,
JPCRR features scientific articles from a
broad spectrum of disciplines. Past issues
include original research manuscripts,
state-of-the-art reviews and editorials
on controversial topics. Double-blind
peer review ensures fair decisions for
all submissions regardless of authors’
institutional affiliation.

The current issue features original
research on the association of body
surface area and percutaneous coronary
intervention outcomes as well as the
effect of unused cardiac device leads on
future complications.
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For a complete list of article types and
author instructions, please visit the
journal’s open-access website:
www.aurora.org/jpcrr.
For questions, contact JPCRR Editor-inChief Dennis J. Baumgardner, MD, at
dennis.baumgardner@aurora.org ■

Aurora Cardiovascular Services
Medical education events

PHYSICIAN RECRUITMENT
Electrophysiology

To request information or to register, please contact Laurel Landis at 414-219-7684
or laurel.landis@aurora.org. ■
April 11, 2015 l Pewaukee, WI

May 30, 2015 l Milwaukee, WI

New Developments in Cardiology:
A Comprehensive Review of Cardiology
and Vascular Medicine Issues

The Milwaukee Heart Failure
Symposium 2015
Course Director: Nasir Sulemanjee, MD

Course Directors: Tanvir Bajwa, MD;
Suhail Allaqaband, MD; Jayant Khitha, MD

July 20, Oct. 26 l Milwaukee, WI

May 2-3, 2015 l Milwaukee, WI

Greater Milwaukee Heart Failure
Society Series

Echo Milwaukee

Jule Wetherbee, MD
Electrophysiologist

Course Director: Nasir Sulemanjee, MD

Course Directors: A. Jamil Tajik, MD;
Bijoy Khandheria, MD; Chris Kramer, RDCS;
Matt Umland, RDCS
May 28, 2015 l Milwaukee, WI
Patient Education Day (Non-CME Event)

Dec. 3-5, 2015 l Chicago, IL
AF/VT/VF Summit
Course Directors: Jasbir Sra, MD;
Masood Akhtar, MD

A day of information and fellowship
for patients with implantable
cardioverter defibrillators
Hosts: Masood Akhtar, MD;
Kathi Axtell, RN

Dr. Wetherbee joined
Aurora Cardiovascular Services as an
electrophysiologist in August.
She completed a residency in internal
medicine and a fellowship in cardiology
and cardiac electrophysiology at Medical
College of Wisconsin. Dr. Wetherbee
is board certified in cardiovascular disease,
clinical cardiac electrophysiology and
internal medicine. She is interested in all
areas of cardiac electrophysiology, from
providing diagnoses for heart rhythm
disorders to management and treatment. ■

Aurora Cardiovascular Services
Transcatheter Aortic Valve Replacement (TAVR) and MitraClip procedures

TAVR Volumes
MitraClip
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2012

2013

2014

30

67

110

199

2

4

2

17

Total patients evaluated: 1,076
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